Binh Ba Ngo

Binh BaNgo

Ngô Bá Bình · Ngo Ba Binh

Twenty-six years building diagnostics companies. Two sold to listed global groups. Now developing Australian-branded diagnostic kits in Queensland.

  • 26years in diagnostics
  • 8companies co-founded
  • 2sales to listed groups
  • AU$122Mbusiness value created

View verified careerReview research and sources

Portrait of Binh Ba Ngo (Ngô Bá Bình)

Current leadership roles

  • Founder and OwnerInogen Pty Ltd
  • ChairEramic Technology Era JSC
  • Vice ChairmanPhu Thai Pharmaceutical JSC
  • Board MemberPhacogen Group

01In figures

  • AU$122Mbusiness value created
  • 26years in diagnostics
  • 8companies co-founded
  • 2sales to listed global groups
  • 5testing categories created

02Profile

Binh Ba Ngo is a serial entrepreneur in molecular diagnostics, a field where scientific, regulatory and clinical barriers meet.

He has co-founded eight companies. Two were acquired by listed global groups, Gentis by Eurofins Scientific and Biomedic by DKSH, and in both cases he was retained through and beyond completion. Acquirers rarely keep founders.

His method is repeatable. He identifies a diagnostic capability proven internationally but missing from the local market, then builds everything it needs to become standard practice: the technology, regulatory approval, laboratory, team and an economic model the health system can sustain. Five categories of medical testing became routine in Vietnam's leading hospitals this way.

He combines three capabilities that rarely sit in one person: scientific direction as a molecular biologist, full profit and loss responsibility at group scale, and personal leadership of both company sales. Through Inogen, he is moving product development, testing and certification to Australia, creating Australian-branded kits priced below imports and built for international markets.

Binh Ba Ngo at a meeting with colleagues
Meeting at Phú Thái Pharma.

03Career

Career

Current and past roles.

Selected contribution

September 2022 to present

Provides board-level oversight at Phacogen Group.

  1. September 2022 to present

    Phacogen Group, Hanoi

    Board Member

    Provides board-level oversight at Phacogen Group.

  2. 2022 to present

    Eramic Technology Era JSC

    Chair of the Board of Directors

    Directed research that discovered two new probiotic strains, published in peer-reviewed journals.

  3. 2021 to present

    Phu Thai Pharmaceutical JSC

    Vice Chairman of the Board

    Oversees product development and financial governance as Vice Chairman.

  4. From August 2025

    Inogen Pty Ltd, Queensland

    Founder and Chief Operating Officer

    Founded Inogen to develop Australian-branded diagnostic kits in Queensland for international markets.

  5. October 2024 to September 2026

    Biomedic Joint Stock Company, Hanoi

    Co-Founder and Chief Operating Officer

    Led Biomedic as Chief Executive through its acquisition by Swiss-listed DKSH, and continues to lead it after the sale.

  6. 2014 to March 2025

    Tâm Việt Medical Equipment and Science Co. Ltd, Hanoi

    Director and legal representative

    Directed and legally represented Tâm Việt's medical equipment business for more than a decade.

  7. 2010 to 2025

    Gentis Joint Stock Company, Hanoi

    Co-Founder and Board Director

    Built Gentis into Vietnam's largest genetic testing group, an eleven-branch national network, and personally led its sale to Eurofins Scientific.

GENTIS 13th anniversary stage, Hạ Long, October 2023
GENTIS, 2023GENTIS 13th anniversary, Hạ Long, 25 October 2023.

04Family archive

A working life in diagnostics

Moments from his work across GENTIS, Biomedic and international scientific meetings, spanning 2019 to 2025.

Binh Ba Ngo signing documents at his office
Binh Ba Ngo signing documents at his office.
Binh Ba Ngo receiving recognition at Biomedic's 2025 year-end gathering
Receiving recognition at Biomedic's 2025 year-end gathering.
Binh Ba Ngo at the ESMO Congress in October 2025
At the ESMO Congress, 17 to 21 October 2025.
Binh Ba Ngo at GENTIS's ninth-anniversary gathering in October 2019
At GENTIS's ninth-anniversary gathering in October 2019.
Binh Ba Ngo at the GENTIS 2022 year-end gathering
At the GENTIS 2022 year-end gathering.
Seven attendees in front of the GENTIS 13th anniversary backdrop
GENTIS 13th anniversary, Hạ Long, 25 October 2023.
Biomedic's 17th-anniversary celebrationA silent recording of company representatives gathered for the anniversary cake ceremony.

05Selected achievements

Selected achievements

  1. 01

    Built Gentis into Vietnam's largest genetic testing group, an eleven-branch national network, sold to Eurofins Scientific in 2025.

  2. 02

    Lifted the Gentis sale value by fifty per cent before completion, with no new capital and no dilution to the founders.

  3. 03

    Led Biomedic as Chief Executive through its acquisition by Swiss-listed DKSH, and continues to lead it after the sale.

  4. 04

    Created five testing categories now standard in leading hospitals: prenatal screening, embryo testing for IVF, inherited cancer risk, gene testing to guide cancer treatment and forensic DNA identification.

  5. 05

    Directed research that discovered two new probiotic strains, published in peer-reviewed journals.

06Research and publications

Research

Binh Ba Ngo's research concerns the characterisation and safety assessment of probiotic Bacillus subtilis strains isolated in Vietnam, undertaken with colleagues at Eramic Technology Era JSC. Between 2025 and 2026 the group published three peer-reviewed studies describing the genome and the in vitro safety profile of two strains, Eramic 25 and Eramic 26. His contribution to the genome study is recorded as project administration and supervision.

2025Genome report of a probiotic Bacillus subtilis strain isolated from healthy human feces in VietnamMicrobiology Resource AnnouncementsAbstract and citation

Le Thi H, Hoang Thi Thanh H, Dao Gia B, Doan Thi Thuy L, Luu Thi Thuy N, Nguyen Huu A, Bui Nhat L, Vuong Quang T, Dao Tuyet M, Ngo Ba B, Nguyen Vu T. Microbiology Resource Announcements. 2025;14(10):e00513-25. doi:10.1128/mra.00513-25. PubMed Central

This genome announcement reports the draft genome of B. subtilis strain Eramic25, isolated in 2022 from a stool sample collected from a healthy volunteer in Hanoi under ethics approval 637/QĐ-ĐHYHN. The genome was sequenced on the Illumina MiSeq platform and assembled de novo, yielding a 3,855,385 bp draft genome with a GC content of 43.53% and 4,247 predicted protein-coding sequences, and multilocus sequence typing assigned the strain to sequence type ST123. Screening for virulence determinants confirmed the absence of the major toxin genes bceT, hblABC, nheABC, cytK, entFM and cesB, supporting the strain's safety profile as a probiotic candidate. The sequence is deposited in GenBank under accession GCA_031932165.1.

2025Comprehensive in vitro assessment of the safety profile of Bacillus subtilis Eramic 25 and its potential for application in the development of functional foods and health supplementsTạp chí Dinh dưỡng và Thực phẩm (Vietnam Journal of Nutrition and Food)Abstract and citation

Đoàn Thị Thùy Linh, Đào Gia Bách, Lưu Thị Thủy Ngân, Ngô Bá Bình, Hoàng Thị Thanh Hoa, Nguyễn Vũ Trung, Lê Thị Hội. Tạp chí Dinh dưỡng và Thực phẩm (Vietnam Journal of Nutrition and Food). 2025;21(3). doi:10.56283/1859-0381/892. Journal record

This study assessed the in vitro safety of B. subtilis Eramic 25 according to the Generally Recognised as Safe (GRAS) criteria of the United States Food and Drug Administration and the guidance of the European Food Safety Authority. The strain was tested for activity against pathogenic bacteria and for cytotoxicity in the Vero and HT-29 cell lines, and its genome was screened for virulence and antibiotic resistance genes. Eramic 25 showed no cytotoxicity in either cell line and carried no toxin-encoding or haemolysin genes, and its antibiotic resistance genes were not located on plasmids or mobile genetic elements, indicating a very low risk of antibiotic resistance gene transfer. The findings provide a basis for further studies in animals and clinical trials in humans.

2026Research and safety evaluation of the Bacillus subtilis Eramic 26 strain for application in probiotic productionVietnam Journal of Science and TechnologyAbstract and citation

Đoàn Thị Thùy Linh, Đào Gia Bách, Lưu Thị Thủy Ngân, Ngô Bá Bình, Hoàng Thị Thanh Hoa, Nguyễn Vũ Trung, Lê Thị Hội. Vietnam Journal of Science and Technology. 2026;68(2). doi:10.31276/VJST.2025.3525. Journal record

This study evaluated the safety of B. subtilis Eramic 26 in accordance with GRAS guidance from the FDA and EFSA, through antibacterial activity testing against five indicator organisms (Escherichia coli, Salmonella Typhimurium, Enterococcus faecium, Staphylococcus aureus and Shigella flexneri), haemolysis and cytotoxicity assays in HT-29 and Vero cells, and genomic analysis of virulence and antibiotic resistance determinants. The strain showed no cytotoxic effect in either cell line. The resistance genes identified, including fosB, satA and ydhE/norM, together with mutations in gyrA and gyrB, were chromosomal and not associated with mobile genetic elements, and the strain carried genes for the bacteriocins bacilysin and subtilosin. The findings indicate that Eramic 26 is a safe strain with strong potential for application in probiotic production.

07Documents and articles

Documents and articles

Peer-reviewed papers and public articles that name Binh Ba Ngo. Each item links to the publisher or journal record rather than a private copy.

  1. Research paper2025Genome report of a probiotic Bacillus subtilis strain isolated from healthy human feces in VietnamMicrobiology Resource Announcements. DOI 10.1128/mra.00513-25.
  2. Research paper2025Comprehensive in vitro assessment of the safety profile of Bacillus subtilis Eramic 25 and its potential for application in the development of functional foods and health supplementsTạp chí Dinh dưỡng và Thực phẩm (Vietnam Journal of Nutrition and Food). DOI 10.56283/1859-0381/892.
  3. Research paper2026Research and safety evaluation of the Bacillus subtilis Eramic 26 strain for application in probiotic productionVietnam Journal of Science and Technology. DOI 10.31276/VJST.2025.3525.
  4. Published article2022Công ty GENTIS chính thức gia nhập thành viên Tập đoàn EurofinsSức Khỏe & Đời Sống, 10 February 2022. Report on GENTIS joining the Eurofins group, naming the newly elected board, including Ngô Bá Bình.
  5. Published article2022Tập đoàn Eurofins rót vốn đầu tư vào GentisVnExpress, 2 March 2022. Sponsored content supplied by GENTIS reporting the Eurofins investment and naming Binh Ba Ngo among the new board members.
  6. Published article2023GENTIS kỷ niệm 13 năm thành lậpGENTIS, October 2023. The company's 13th anniversary, listing Ngô Bá Bình as a board member.
  7. Company profile2026Phó Chủ tịch, Phát triển Sản phẩm và Quản trị Tài chínhPhú Thái Pharma, company profile of Ngô Bá Bình as Vice Chairman.